Illumina has named Bill Bonnar as senior vice president of operations. In this newly created role, Bonnar will be responsible for overseeing Illumina's global manufacturing and supply chain efforts.
Bonnar joins Illumina from KLA-Tencor, a semiconductor equipment provider, where he held several senior operations management positions. He also worked at Procter and Gamble as a production manager and controls engineer.
Bonnar holds an MBA from Santa Clara University and a BS in electrical engineering from California Polytechnic University.
Terms of the employment called for Illumina to grant Bonnar an option to purchase 200,000 shares of Illumina's common stock.
Jon Kayyem and Mark Lappe have joined the board of directors of Osmetech as non-executive chairman and non-executive director, respectively. Kayyem and Lappe are co-founders of Efficacy Capital, which runs a family of biotech funds.
Kayyem is a founder of Clinical Micro Sensors, now Osmetech’s molecular diagnostics subsidiary. He holds a PhD in molecular biology from CalTech. Lappe is the founder of Lappe & Associates, an executive search firm that serves early-stage life sciences companies.
Osmetech also said that directors Gordon Hall and Gordon Kuenster have left its board and that Daryl Faulkner will step down as chairman but will remain as a non-executive director.
Decision Biomarkers recently announced the formation of a scientific advisory board.
DBI’s SAB includes: Daniel Chan, director of the Center for Biomarker Discovery at Johns Hopkins Medical Institution in Baltimore; Johann de Bono, senior lecturer at the Institute for Cancer Research at the Royal Marsden Hospital in London; John Heymach, assistant professor of thoracic head and neck medical oncology at the University of Texas MD Anderson Cancer Center in Houston; Peter Maimonis, vice president of biological research at DBI; and Larry Oliver, scientific director of the Metals Laboratory in the department of laboratory medicine and pathology at the Mayo Clinic in Rochester, Minn.